公开(公告)号：US20180263998A1

公开(公告)日：2018-09-20

申请号：US15516567

申请日：2015-10-08

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Yasuhiro Zaima ,  Kazuo Kazama ,  Shuntaro Arase ,  Kentaro Nagane ,  Kanta Horie ,  Yosuke Ueki

IPC: A61K31/542

CPC classification number: A61K31/542 ,  A61K9/2018 ,  A61K9/2054 ,  A61P25/28

Abstract: The present invention provides a pharmaceutical composition comprising a compound represented by formula (1): or N-[3-((4aS,5R,7aS)-2-amino-5-methyl-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]thiazin-7a-yl)-4-fluorophenyl]-5-difluoromethylpyrazine-2-carboxamide, or a pharmaceutically acceptable salt of the foregoing, and a salt of a compound having a C12-22 saturated aliphatic hydrocarbon group.

公开(公告)号：US10117876B2

公开(公告)日：2018-11-06

申请号：US15516567

申请日：2015-10-08

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Yasuhiro Zaima ,  Kazuo Kazama ,  Shuntaro Arase ,  Kentaro Nagane ,  Kanta Horie ,  Yosuke Ueki

IPC: A61K31/542 ,  C07D513/04 ,  A61K9/20

CPC classification number: A61K31/542 ,  A61K9/2018 ,  A61K9/2054 ,  A61P25/28

Abstract: The present invention provides a pharmaceutical composition comprising a compound represented by formula (1): or N-[3-((4aS,5R,7aS)-2-amino-5-methyl-4a,5,7,7a-tetrahydro-4H-furo[3,4-d] [1,3]thiazin-7a-yl)-4-fluorophenyl]-5-difluoromethylpyrazine-2-carboxamide, or a pharmaceutically acceptable salt of the foregoing, and a salt of a compound having a C12-22 saturated aliphatic hydrocarbon group.

公开(公告)号：US10076524B1

公开(公告)日：2018-09-18

申请号：US15516567

申请日：2015-10-08

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Yasuhiro Zaima ,  Kazuo Kazama ,  Shuntaro Arase ,  Kentaro Nagane ,  Kanta Horie ,  Yosuke Ueki

IPC: A61K31/542 ,  C07D513/04 ,  A61K9/20

CPC classification number: A61K31/542 ,  A61K9/2018 ,  A61K9/2054 ,  A61P25/28

Abstract: The present invention provides a pharmaceutical composition comprising a compound represented by formula (1): or N-[3-((4aS,5R,7aS)-2-amino-5-methyl-4a,5,7,7a-tetrahydro-4H-furo[3,4-d] [1,3]thiazin-7a-yl)-4-fluorophenyl]-5-difluoromethylpyrazine-2-carboxamide, or a pharmaceutically acceptable salt of the foregoing, and a salt of a compound having a C12-22 saturated aliphatic hydrocarbon group.